Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821551 | 1.00 | BACE1 (0.35) | BACE1SMYD2SSTR4 | |
| SCHEMBL19896125 | 0.90 | BACE1 (0.35) | BACE1SMYD2SSTR4 | |
| SCHEMBL16211787 | 0.90 | BACE1 (0.35) | BACE1SMYD2SSTR4 | |
| SCHEMBL19896128 | 0.90 | BACE1 (0.35) | BACE1SMYD2SSTR4 | |
| SCHEMBL19896122 | 0.90 | BACE1 (0.35) | BACE1SMYD2SSTR4 | |
| SCHEMBL30936052 | 0.90 | BACE1 (0.35) | BACE1SMYD2SSTR4 | |
| SCHEMBL22194924 | 0.88 | BACE1 (0.34) | BACE1 | |
| SCHEMBL22194922 | 0.88 | BACE1 (0.34) | BACE1 | |
| SCHEMBL22194926 | 0.88 | BACE1 (0.34) | BACE1 | |
| SCHEMBL30107195 | 0.88 | BACE1 (0.34) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391930-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | GENENTECH, INC. | 2024-11-28 | — | — | US | disclosed |
| US-11046649-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391930-A1 | SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, SGMS1, PMP22 | BACE1 951/4885SMYD2 1365/4885SSTR4 4779/4885 |
| US-11046649-B2 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | IDO1, IDO2, TDO2 | BACE1 2734/4885SMYD2 1522/4885SSTR4 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.